GlassScriptPhysician profile
Steven A Pally
NPI 1114921079
$7,621.91
in general payments reported to CMS, 2019-2025
57 companies · $799 in 2025
The $799 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,327 · 2020: $1,114 · 2021: $1,237 · 2022: $1,150 · 2023: $1,077 · 2024: $918 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,794.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,367.64 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $915.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $839.34 | 2019-2025 | |
| Amgen INC. | $651.35 | 2019-2025 | Repatha, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $424.70 | 2019-2025 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $338.91 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $317.73 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.87 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $211.69 | 2019-2024 | |
| Ibsa Pharma INC. | $175.37 | 2019-2025 | Tirosint, Licart, Licart |
| Novartis Pharmaceuticals Corporation | $134.35 | 2023-2025 | |
| Glaxosmithkline, LLC. | $131.35 | 2019-2024 | Trelegy Ellipta |
| Arbor Pharmaceuticals, INC. | $113.07 | 2019-2022 | |
| Vivus LLC | $108.29 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.43 | 2020-2023 | Xifaxan, Trulance, Cycloset |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Pally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.